This database was last updated in October 2019 and should only be used as a historical snapshot. There may be new information that is not included here.
Scott Gottlieb departed April 5, 2019
Health and Human Services (joined: May 9, 2017)
Commissioner, Food and Drug Administration | Financial Disclosure »
Bio, via Department of Health and Human Services:
Dr. Scott Gottlieb was sworn in as the 23rd Commissioner of Food and Drugs on May 11, 2017. Dr. Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA's Deputy Commissioner for Medical and Scientific Affairs and before that, as a senior advisor to the FDA Commissioner. He also worked on implementation of the Medicare drug benefit as a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly as it related to new medical technologies. In 2013 Dr. Gottlieb was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on healthcare information technology. Dr. Gottlieb was previously a Resident Fellow at the American Enterprise Institute, and a Clinical Assistant Professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York, New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.
Former Positions Outside Government
- American Enterprise Institute Resident Fellow
- American Pathology Partners (AP2) Member of the Board of Directors (New Enterprise Associates (NEA) portfolio company. Position held in conjunction with professional responsibilities to NEA.)
- BDO Center for Healthcare Excellence & Innovation Independent Senior Advisor
- Cell BioTherapy, Inc Acting CEO and Director (Position held through considerations related to T.R. Winston)
- Collective Health Advisory Board Member (Position held through considerations related to NEA)
- CombiMatrix Independent Member of the Board of Directors
- Daichii Sankyo U.S. Independent Member of the Board of Directors
- Emmaus Life Sciences Member of the Board of Directors (Position held through considerations related to T.R. Winston)
- Forbes Magazine LLC Contributing Writer
- GlaxoSmithKline plc Independent Member of the R&D Portfolio Investment Board
- Glytec Independent Member of the Board of Directors
- Gradalis and Strike Bio Independent Member of the Board of Directors
- Innovating Healthcare LLC Managing Member (Contracting entity for independent consulting work related to Bristol Meyers Squibb. This LLC is currently inactive since December 2016.)
- Kure Member of the Board of Directors (Position held through considerations related to T.R. Winston. Uncompensated Postion)
- MedAvante Independent Member of the Board of Directors
- New Enterprise Associates Venture Partner (Venture Partner was Dr. Gottlieb's working title. He received no equity as part of his compensation. The notation of "partner" in his title should not be assumed to imply that he had carried interest in the firm's venture funds. He had no such equity interest.)
- New York University School of Medicine Clinical Assistant Professor (Uncompensated Postion)
- Scott Gottlieb, MD Consulting Sole Proprietor
- Society of Hospital Medicine Independent Member of the Policy Board (Uncompensated Postion)
- T.R. Winston & Company Managing Director (Managing Director was Dr. Gottlieb's working title. He received no equity in the firm as part of his compensation. He was paid for consulting services. His working title should not be assumed to imply that he had carried interest. He had no such equity interest.)
- Tivorsan Pharmaceuticals Acting Co-CEO (Position held through considerations related to T.R. Winston)
- Tolero Pharmaceuticals Independent Member of the Board of Directors
- YourEncore Consultant (Contracting entity for independent consulting work related to Vertex Pharmaceuticals)
Former Compensation Sources
- Academy of Managed Care Pharmacy Speaking Honorarium (booked through WorldWide Speakers Group)
- American Enterprise Institute Resident Fellow
- Angion Pharmaceuticals Payment made to T.R. Winston for professional services
- Association for Accessible Medicines Speaking Honorarium (booked through WorldWide Speakers Group)
- Avalere Health Independent Consultant
- BDO Center for Healthcare Excellence & Innovation Independent Senior Advisor
- Bausch & Lomb Speaking Honorarium (Work performed for Bausch & Lomb, which was a subsidiary of Valeant Pharmaceuticals North America LLC. Paying entity was Virtuoso Healthcare Communications)
- Biogen Idec Speaking Honorarium (booked through WorldWide Speakers Group)
- Bristol Meyers Squibb (Also paid through Innovating Healthcare LLC) Independent Consultant (Work performed under a consulting arrangement with Innovating Healthcare LLC)
- Cahill Gordon & Reindel Independent Expert (In conjunction with legal services provided for Amarin Pharmaceuticals)
- Celgene Corporation Payment made to T.R. Winston for professional services
- Cell BioTherapy, Inc Acting CEO and Director
- Clinical Care Targeted Communications Speaking Honorariums (Related to three separate speaking engagements for the American Journal of Managed Care and for the publication's Patient-Centered Oncology Care forum.)
- Coda Octopus Group, Inc Payment made to T.R. Winston for professional services
- Combimatrix Corporation Independent Member of the Board of Directors
- DCI Group LLC Unpublished Expert White Paper
- Daichii Sankyo U.S. Independent Member of the Board of Directors
- FujiFilm USA Payment made to T.R. Winston for professional services
- Generic Pharmaceutical Association Speaking Honorarium (booked through WorldWide Speakers Group)
- GlaxoSmithKline plc Independent Member of the Portfolio Investment Board
- Glytec Independent Member of the Board of Directors
- Goldman Sachs & Co Speaking Honorarium (booked through WorldWide Speakers Group)
- Gradalis and Strike Bio Independent Member of the Board of Directors
- Health Insights Speaking Honorarium (booked through WorldWide Speakers Group)
- Healthcare Distribution Management Association Speaking Honorarium (booked through WorldWide Speakers Group)
- Institute for International Research Speaking Honorarium (booked through WorldWide Speakers Group)
- Jeffries & Company, Inc. Speaking Honorariums (booked through WorldWide Speakers Group)
- Johnson & Johnson Speaking Honorarium (booked through WorldWide Speakers Group)
- KURE Payment made to T.R. Winston for professional services
- Kaye Scholer LLP Independent Expert (In conjunction with legal services provided for King Pharmaceuticals)
- Lincoln Healthcare HomeCare 100 Speaking Honorarium (booked through WorldWide Speakers Group)
- Lincoln Healthcare Hospital 100 Speaking Honorarium (booked through WorldWide Speakers Group)
- Mallinckrodt Pharmaceuticals Speaking Honorarium (booked through WorldWide Speakers Group)
- MedImpact Healthcare Systems, Inc Speaking Honorariums (booked through WorldWide Speakers Group)
- Merck & Co, Inc. Speaking Honorariums (booked through WorldWide Speakers Group)
- Morgan, Lewis & Bockius LLP Independent Expert (In conjunction with legal services provided for Baxalta Corporation)
- National Comprehensive Cancer Network Speaking Honorariums (For two separate events on 9/11/15 and 11/18/15 and 4/1/16)
- New Enterprise Associates Venture Partner
- Omeros Independent Consultant
- Pharma-Bio Serv Payment made to T.R. Winston for professional services
- Prosetta BioSciences Payment made to T.R. Winston for professional services
- Scott Gottlieb, MD Consulting Independent Consulting Business
- Stifel, Nicolaus & Company Speaking Honorarium (booked through WorldWide Speakers Group)
- Synthesis Energy Payment made to T.R. Winston for professional services
- T.R. Winston & Company Managing Director
- Thermo Fisher Scientific Speaking Honorarium (booked through WorldWide Speakers Group)
- Tivorsan Pharmaceuticals Payment made to T.R. Winston for professional services
- Tolero Pharmaceuticals Independent Member of the Board of Directors
- University of Tennessee College of Medicine Speaking Honorarium (booked through WorldWide Speakers Group)
- Vertex Pharmaceuticals (Through YourEncore) Independent Consultant (Work performed under a consulting arrangement with YourEncore.)
- inVentiv Health Inc. Speaking Honorarium (booked through WorldWide Speakers Group)
Employment Assets
| Description | Value | Income |
|---|---|---|
| American Enterprise Institute (Think Tank) | $210,916 | |
| CREF Global Equities AEI Retirement Plan | $100,001 - $250,000 | None (or less than $201) |
| New Enterprise Associates (Venture Capital) | $280,000 | |
| BDO Center for Healthcare Excellence & Innovation | $180,000 | |
| GlaxoSmithKline plc (Drug Company) | $87,153 | |
| Daichii Sankyo U.S. (Drug Company) | $52,207 | |
| Tolero Pharmaceuticals (Biotech Company) | $37,500 | |
| Tolero Pharmaceuticals Stock Options | None (or less than $1,001) | $193,111 |
| Forbes Magazine LLC (Publishing Company) | $2,864 | |
| Eagle Small Cap Growth Fund (MUTF:HRSCX) | $100,001 - $250,000 | $2,501 - $5,000 |
| PIMCO Total Return Fund (MUTF:PTTRX) | $15,001 - $50,000 | $1,001 - $2,500 |
| DFA U.S. Small Cap Value Fund (MUTF:DFSVX) | $1,001 - $15,000 | $201 - $1,000 |
| Emmaus Life Sciences (Biotech Company ) | $4,500 | |
| American Pathology Partners stock options (value not readily ascertainable): 220,000 options to purchase shares @ $.04/share expires 08/13/2022. Vested | None (or less than $201) | |
| Gradalis and Strike Bio (Biotech Company) | $65,000 | |
| Gradalis and Strike Bio Stock Options (value not readily ascertainable) Strike Bio 25,000 Options to purchase shares at $1.93/Share expires 05/15/24; Gradalis 25,000 Options to purchase shares at 3.16/Share expires 03/21/26 and 25,000 Options to purchase shares at $3.57/Share expires 05/15/24. Vested | None (or less than $201) | |
| Glytec Stock Options (value not readily ascertainable) 15,000 Options to purchase shares at $1.35/Share expires 02/13/24 and 5,578 Options to purchase shares at $7.60/Share expires 02/13/25 and 6,101 Options to purchase shares at $5.71/Share expires 06/01/26. Vested | None (or less than $201) | |
| FPA Capital Fund (MUTF:FPPTX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Marsico Focus Fund (MUTF:MFOCX) | $15,001 - $50,000 | $201 - $1,000 |
| Scott Gottlieb, MD Consulting (Independent Consulting Business) | $81,767 | |
| Doubleline Total Return Bond Fund (MUTF: DLTNX) | $1,001 - $15,000 | $201 - $1,000 |
| T Rowe Price Global Stock Fund (MUTF:PRGSX) | $50,001 - $100,000 | $1,001 - $2,500 |
| Wintergreen Fund (MUTF:WGRNX) | $1,001 - $15,000 | $201 - $1,000 |
| First Eagle Global Fund Class A (MUTF:SGENX) | $1,001 - $15,000 | $201 - $1,000 |
| iShares Select Dividend ETF (NYSE:DVY) | $1,001 - $15,000 | $201 - $1,000 |
| Weitz Partners III Opportunity Fund (MUTF:WPOPX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Wasatch International Opportunities Fund (MUTF:WAIOX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Wasatch Small Cap Growth (MUTF:WAAEX) | $15,001 - $50,000 | $1,001 - $2,500 |
| CombiMatrix Options (value not readily ascertainable) Surrendered in their Entirety Upon Resignation from the Board of Directors 12/19/16 | None (or less than $1,001) | None (or less than $201) |
| Columbia European Equity Fund (MUTF:AXEAX) | $1,001 - $15,000 | $201 - $1,000 |
| Akre Focus Fund Retail (MUTF:AKREX) | $15,001 - $50,000 | $201 - $1,000 |
| Franklin Mutual European Fund (MUTF:TEURX) | $1,001 - $15,000 | $201 - $1,000 |
| T. Rowe Price European Stock Fund (MUTF:PRESX) | $1,001 - $15,000 | $201 - $1,000 |
| Oakmark Fund (MUTF:OAKMX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Longleaf Partners Fund (MUTF:LLPFX) | $100,001 - $250,000 | $2,501 - $5,000 |
| FPA Crescent Fund (MUTF:FPACX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Fidelity Japan Smaller Companies (MUTF:FJSCX) | $15,001 - $50,000 | $201 - $1,000 |
| Powershares DB Commodity Index ETF (NYSE:DBC) | $1,001 - $15,000 | $201 - $1,000 |
| iShares Select Dividend ETF (NYSE:DVY) | $1,001 - $15,000 | $201 - $1,000 |
| iShares MSCI Emerging Markets ETF (NYSE:EEM) | $15,001 - $50,000 | $1,001 - $2,500 |
| iShares MSCI Eurozone ETF (NYSE:EZU) | $15,001 - $50,000 | $1,001 - $2,500 |
| Innovating Healthcare LLC | $49,000 | |
| Van Eck Vectors Natural Resources ETF (NYSE:HAP) | $1,001 - $15,000 | $201 - $1,000 |
| Lillis Energy (NASDAQ:LLEX) | $50,001 - $100,000 | None (or less than $201) |
| Lyrical U.S. Value Equity Fund (MUTF:LYRBX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Van Eck Vectors Agribusiness ETF (NYSE:MOO) | $1,001 - $15,000 | $201 - $1,000 |
| Pimco Commodity Real Return (MUTF:PCRDX) | $1,001 - $15,000 | $201 - $1,000 |
| iShares TIPS Bond ETF (NYSE:TIP) | $100,001 - $250,000 | $2,501 - $5,000 |
| SPDR DoubleLine Total Return Tact ETF (NYSE:TOTL) | $250,001 - $500,000 | $2,501 - $5,000 |
| Vanguard Index Reit ETF (NYSE:VNQ) | $15,001 - $50,000 | $201 - $1,000 |
| Vanguard Index Growth ETF (NYSE:VUG) | $1,001 - $15,000 | $201 - $1,000 |
| Weitz Partners III Opportunity Fund (MUTF:WPOPX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Sector SPDR Energy ETF (NYSE:XLE) | $50,001 - $100,000 | $1,001 - $2,500 |
| Sector SPDR Utilities ETF (NYSE:XLU) | $1,001 - $15,000 | $201 - $1,000 |
| Tivorsan Pharmaceuticals Warrants (value not readily ascertainable) 256,506 Warrants to purchase shares at $0.01/Share expires 11/25/20. Vested | None (or less than $201) | |
| Combimatrix Corporation | $30,662 | |
| Collective Health Options (value not readily ascertainable) 200,000 options to purchase shares at $.024/Share expires 08/27/24. Vested | None (or less than $201) | |
| T.R. Winston & Company (Merchant Bank) | $1,849,784 | |
| Social Reality (NASDAQ:SRAX) Warrants (value not readily ascertainable) 16,000 warrants to purchase shares at $7.50/Share expires 10/30/17 and 7,000 warrants to purchase shares at $5.00/Share expires 08/22/18. Vested | None (or less than $201) | |
| Angion Pharmaceuticals Warrants (value not readily ascertainable) 85.62 warrants to purchase shares at $1,247.94/Share expires 09/06/21. Vested | None (or less than $201) | |
| Synthesis Energy Systems, Inc. (NASDAQ:SYMX) Warrants (value not readily ascertainable) 50,000 warrants to purchase shares at $2.25/Share expires 09/28/17. Vested | None (or less than $201) | |
| Lillis Energy, Inc (NASDAQ:LLEX) Warrants (value not readily ascertainable) 5,000 warrants to purchase shares at $25.00/Share expires 08/01/17. Vested | None (or less than $201) | |
| Emmaus Life Sciences, Inc Warrants (value not readily ascertainable) 54,000 warrants to purchase shares at $3.50/Share expires 09/11/18. Vested | None (or less than $201) | |
| Pharma-Bio Serv Inc (NASDAQ:PBSV) Warrants (value not readily ascertainable) 275,000 warrants to purchase shares at $1.80/Share expires 12/01/19. Vested | None (or less than $201) | |
| Prosetta Biosciences Warrants (value not readily ascertainable) 40,000 warrants to purchase shares at $4.50/Share expires 02/11/21. Vested | None (or less than $201) | |
| Neuralstem, Inc (NASDAQ:CUR) Warrants (value not readily ascertainable) 22,308 warrants to purchase shares at $39.00/Share expires 08/13/18. Vested | None (or less than $201) | |
| Inspyr Therapeutics, Inc (NASDAQ:NSPX) Warrants (value not readily ascertainable) 667 warrants to purchase shares at $52.50/Share expires 08/20/18 and 889 warrants to purchase shares at $45.00/Share expires 08/20/18. Vested | None (or less than $201) | |
| MedAvante Stock Options (value not readily ascertainable) 50,000 Options to purchase shares at $3.25/Share. Vested | None (or less than $201) | |
| Combimatrix (NASDAQ:CBMX) 4,804 Shares | None (or less than $1,001) | None (or less than $201) |
| Cell Biotherapy, Inc Options (value not readily ascertainable) 101,961 options to purchase shares at $1.00/Share expires 7/21/26. Vested | None (or less than $201) | |
| Tolero Pharmaceuticals Contingent Value Rights (CVR fully vested. Value not readily ascertainable) 97,946 Shares | None (or less than $201) | |
| Goldman Sachs & Co. - 01/05/16 (Booked through WorldWide Speakers Bureau) | $7,500 | |
| Merck & Co, Inc - 01/25/16 and 03/29/16 (Booked through WorldWide Speakers Group) | $10,000 | |
| InVentiv Health Inc. - 01/12/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Lincoln Healthcare HomeCare 100 - 02/8/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Generic Pharmaceutical Association - 02/24/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Biogen Inc. - 04/12/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Thermo Fisher Scientific - 06/15/16 (Booked through WorldWide Speakers Group) | $7,000 | |
| Institute for International Research - 09/21/16 (Booked through WorldWide Speakers Group) | $7,500 | |
| Healthcare Distribution Management Association - 09/27/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| University of Tennessee College of Medicine - 09/28/16 (Booked through WorldWide Speakers Group) | $7,500 | |
| Lincoln Healthcare Hospital 100 - 10/17/16 (Booked through WorldWide Speakers Group) | $10,000 | |
| Health Insights - 10/27/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Stifel, Nicolaus & Company - 10/28/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Mallinckrodt Pharmaceuticals (Delivered in London) - 11/16/16 (Booked through WorldWide Speakers Group) | $22,500 | |
| Jeffries & Co. London - 11/16/16 (Booked through WorldWide Speakers Group) | $11,250 | |
| Johnson & Johnson - 01/17/17 (Booked through WorldWide Speakers Group) | $11,250 | |
| Association for Accessible Medicines - 02/15/17 (Booked through WorldWide Speakers Group) | $11,250 | |
| CVS Health - 03/29/16 (Booked through WorldWide Speakers Group) | $4,000 | |
| National Comprehensive Cancer Network - 04/01/16 | $3,000 | |
| American Academy of Orthopedic Surgeons - 05/06/16 | $3,000 | |
| HealthCare Royalty Partners - 06/07/16 | $5,000 | |
| Mikart Pharma - 09/28/16 | $5,000 | |
| Association of Independent Physicians - 11/05/16 | $5,000 | |
| GTCR - 02/25/16 (Booked through WorldWide Speakers Group) | $5,000 | |
| YourEncore | $43,200 | |
| iShares U.S. Energy ETF (NYSE:IYE) | $15,001 - $50,000 | $201 - $1,000 |
| VanEck Vector Gold ETF (NYSE:GDX) | $15,001 - $50,000 | $1,001 - $2,500 |
| Op Ed Article. The Four Legs of the New Health-Care System, The Wall Street Journal - 11/30/16 | $200 | |
| Op Ed Article. Clinton’s Stealthy Single-Payer Gambit, The Wall Street Journal - 09/14/16 | $600 | |
| Op Ed Article. How Obama’s FDA Keeps Generic Drugs off the Market, The Wall Street Journal - 08/19/16 | $600 | |
| Op Ed Article. Applying to Zika the Forgotten Lessons of Ebola, The Wall Street Journal - 02/09/16 | $600 | |
| Op Ed Article. Warning: Medicare May Be Bad for Your Heart, The Wall Street Journal - 04/11/16 | $600 | |
| NEA 14 Limited Partnership (passive investor) | None (or less than $1,001) | None (or less than $201) |
| NEA 15 Limited Partnership (passive investor) | None (or less than $1,001) | None (or less than $201) |
| MedAvante Preferred Stock - 95 Series A Preferred Shares and .26% ownership of the MedAvante Co-Invest Fund, for which the only underlying asset is MedAvante Preferred Stock | $15,001 - $50,000 | None (or less than $201) |
| U.S. Renal Care Preferred Stock - 82.946 Class A Preferred Units | $250,001 - $500,000 | None (or less than $201) |
| Radiology Partners Common Stock - 50,000 common shares | $100,001 - $250,000 | None (or less than $201) |
| Bright Health Preferred Stock - 9,796 common and series A preferred shares | $15,001 - $50,000 | None (or less than $201) |
| Collective Health Preferred Stock - 66,540 series B preferred shares | $15,001 - $50,000 | None (or less than $201) |
| Golden State Medical Preferred Stock - 75,000 preferred shares at $1.00/share | $50,001 - $100,000 | None (or less than $201) |
| Angion Pharmaceuticals Preferred Stock - 20 preferred shares | $15,001 - $50,000 | None (or less than $201) |
| Emmaus Life Sciences, Inc Common Stock - 5,988 common shares at $3.50/share | $15,001 - $50,000 | None (or less than $201) |
| Cell BioTherapy Inc Common Stock - 25,000 common shares | $15,001 - $50,000 | None (or less than $201) |
| Kure Common Stock - 97,000 common shares | $1,001 - $15,000 | None (or less than $201) |
| Chanticleer Holdings (NASDAQ:HOTR) Warrants - 8,000 warrants to purchase shares at $1.25/share expires 10/27/19 | None (or less than $1,001) | None (or less than $201) |
| Emmaus Life Sciences, Inc Warrants - 5,988 warrants to purchase shares at $3.50/share expires 09/11/18 | None (or less than $1,001) | None (or less than $201) |
| Glytec Restricted Stock - 17,738 restricted shares | $15,001 - $50,000 | None (or less than $201) |
| MedImpact Speech (Booked through WorldWide Speakers Group) - 03/09/17 | $11,250 | |
| Pharmacy Benefit Managers Institute Speech (Booked through WorldWide Speakers Group) - 03/06/17 | $11,250 | |
| Receivable: GlaxoSmithKline Fourth Quarter 2016 Payment | $1,001 - $15,000 | None (or less than $201) |
| Receivable: GlaxoSmithKline First Quarter 2017 Payment | $1,001 - $15,000 | None (or less than $201) |
| Tolero Pharmaceuticals Common Stock | None (or less than $1,001) | $100,001 - $1,000,000 |
Other Income/Assets
| Description | Value | Income |
|---|---|---|
| Social Reality Stock (NASDAQ:SRAX) | $50,001 - $100,000 | None (or less than $201) |
| SPDR DoubleLine Total Return Tactical ETF (NYSE:TOTL) | $250,001 - $500,000 | $2,501 - $5,000 |
| iShares TIPS Bond ETF (NYSE:TIP) | $50,001 - $100,000 | $1,001 - $2,500 |
| Vanguard REIT Index Fund ETF (NYSE:VNQ) | $1,001 - $15,000 | $201 - $1,000 |
| U.S. Bank Account (cash) | $50,001 - $100,000 | None (or less than $201) |
| U.S. Bank Account (cash) | $15,001 - $50,000 | None (or less than $201) |
| U.S. Bank Account (cash) | $15,001 - $50,000 | None (or less than $201) |
| New Hampshire Moderate Growth Fidelity 529 (Owned across three different dependent child accounts) | $100,001 - $250,000 | None (or less than $201) |
| U.S. Bank Account (cash) | $50,001 - $100,000 | None (or less than $201) |
| Coinbase Account (Bitcoin) | $15,001 - $50,000 | $2,501 - $5,000 |
Employment Agreements and Arrangements
| Employer or Party | City, State | Status and Terms | Date |
|---|---|---|---|
| American Enterprise Institute | Washington, DC, District of Columbia | I will continue to participate in this defined contribution plan. The plan sponsor will not make further contributions after my separation. | June 16, 2002 |
| New York University School of Medicine | New York, New York | I will relinquish this affiliation | Jan. 16, 2011 |
| Tolero Pharmaceuticals | Lehi, Utah | Options have been fully exercised and sold. I will divest myself of the remaining contingent value right. | March 16, 2015 |
| American Pathology Partners (AP2) | Nashville, Tennessee | I will divest my vested stock options. All shares vested | March 16, 2012 |
| Gradalis and Strike Bio | Dallas, Texas | I will divest my vested stock options. All shares vested | June 16, 2014 |
| Glytec | Greenville, South Carolina | I will divest my vested stock options. I will divest my restricted shares. All shares vested | March 16, 2013 |
| MedAvante | Princeton, New Jersey | I will divest my vested stock options. All shares vested | Sept. 16, 2007 |
| CombiMatrix | Irvine, California | Unvested restricted stock units (RSUs) and all options were forfeited in their entirety upon my prior resignation from Board of Directors | Jan. 16, 2009 |
| Scott Gottlieb, MD (The sole proprietorship will be placed into inactive status during my government service and any outstanding fees will be fixed before I enter government.) | Westport, Connecticut | I will continue to participate in this defined contribution plan. The plan sponsor will not make further contributions after my separation. | Sept. 16, 2009 |
| American Enterprise Institute HSA | Washington, District of Columbia | The HSA account will be rolled into a new HSA under the FEHBP | Nov. 15, 2007 |
| Cell BioTherapy, Inc | Los Angeles, California | I will divest my vested stock options. All shares vested | May 16, 2016 |
| Collective Health | San Francisco, California | I will divest my vested stock options. All shares vested | July 16, 2014 |
| Social Reality (Related to professional services delivered by T.R. Winston) | Los Angeles, California | I will divest my stock warrants | Aug. 16, 2013 |
| Angion Pharmaceuticals (Related to professional services delivered by T.R. Winston) | Uniondale, New York | I will divest my stock warrants | Sept. 16, 2016 |
| Tivorsan Pharmaceuticals (Related to professional services delivered by T.R. Winston) | Providence, Rhode Island | I will divest my stock warrants | Jan. 16, 2016 |
| Synthesis Energy Systems, Inc (Related to professional services delivered by T.R. Winston) | Houston, Texas | I will divest my stock warrants | Sept. 16, 2014 |
| Lillis Energy, Inc (Related to professional services delivered by T.R. Winston) | Houston, Texas | I will divest my stock warrants | Jan. 16, 2014 |
| Emmaus Life Sciences (Related to professional services delivered by T.R. Winston) | Los Angeles, California | I will divest my stock warrants | Sept. 16, 2013 |
| Pharma-Bio Serv Inc (Related to professional services delivered by T.R. Winston) | Plymouth Meeting, Pennsylvania | I will divest my stock warrants | April 16, 2015 |
| Prosetta Biosciences (Related to professional services delivered by T.R. Winston) | San Francisco, California | I will divest my stock warrants | Feb. 15, 2016 |
| Neuralstem, Inc (Related to professional services delivered by T.R. Winston) | Germantown, Maryland | I will divest my stock warrants | Aug. 16, 2013 |
| Inspyr Therapeutics, Inc (Related to professional services delivered by T.R. Winston) | San Antonio, Texas | I will divest my stock warrants | Aug. 16, 2013 |
| MedAvante | Hamilton, New Jersey | There could be one-time cash payment to compensate for past, uncompensated consulting and board service from 2007-2017 in the event of a financial sale of the company, in the amount of $400,000. | Sept. 16, 2007 |
| GlaxoSmithKline | Philadelphia, Pennsylvania | Pursuant to the company's compensation arrangement for my service on the Product Investment Board (PIB) I will receive a payment within two months for my service in the fourth quarter of 2016, from October 1, 2016 to December 31, 2016. It will be in the amount of $15,000, reflecting my contracted retainer of $5,000 per month. I will also receive a $15,000 payment for my service during the first quarter of 2017, which will be invoiced on the last day of March 2017 and be payable within 60 days, pursuant to the Company's 60-day payment terms. | Jan. 16, 2010 |
Liabilities
| Creditor Name | Creditor Type | Amount | Rate | Year Incurred |
|---|---|---|---|---|
| Navient Sallie Mae (Loan first acquired in 1995 while a medical student and re-financed in 2002 into a 20-year fixed loan) | Student Loan | $15,001 - $50,000 | 3.50% | 2002 |
| Navient MedLoans (Loan first acquired in 1995 while a medical student and re-financed in 2002 into a 20-year variable loan) | Student Loan | $15,001 - $50,000 | 3.00% | 2002 |
| TD Bank | Exercised Line of Credit | $100,001 - $250,000 | 3.25% | 2016 |
| Caliber Home Loan | Mortgage on Personal Residence | $250,001 - $500,000 | 3.50% | 2013 |
| Bank of America | Mortgage on Personal Residence | $500,001 - $1,000,000 | 4.35% | 2010 |
Spouse's Employment Assets
| Description | Value | Income Type | Income Amount |
|---|---|---|---|
| Doubleline Total Return Bond Fund (MUTF:DLTNX) | $15,001 - $50,000 | $201 - $1,000 | |
| Fidelity Dividend Growth (MUTF:FDGFX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity Diversified International (MUTF:FDIVX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity Equity Income (MUTF:FEQIX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity Mid Cap Stock (MUTF:FMCSX) (Total consulting fee includes reimbursed travel expenses) | $1,001 - $15,000 | None (or less than $201) | |
| Janus Overseas Fund (MUTF:JAOSX) (This total reported fee includes reimbursed travel expenses. It will be reported on the CMS "Open Payments" website in a category marked "promotional speaking/other.") | $1,001 - $15,000 | $201 - $1,000 | |
| Oakmark International Fund (MUTF:OAKIX) | $1,001 - $15,000 | $201 - $1,000 | |
| Fairholme Fund (MUTF:FAIRX) (Options fully exercised and sold) | $1,001 - $15,000 | $201 - $1,000 | |
| Wintergreen Fund (MUTF:WGRNX) | $1,001 - $15,000 | $201 - $1,000 |
Do you know something about Scott Gottlieb? Send us an email at [email protected] or send a Signal message to 347-244-2134.
See more staffers at Health and Human Services »